Little T: "....the small shareholders have next to no influence of the potential takeover price once the suitor has 50.1%...."
Little T/others: Little T: Of course, you are totally correct in what you are stating. I just wonder which 'entity' is that "suitor" that is accumulating and especially at what kind of % they are already at now...? You being in a better position to judge how their accumulation is going can better foresee WHEN (approx.) they will reach that decisive 50.1%, where a take-over will become quickly a fact. Just wonder about two things that you could possibly give your
"guesstimates":
a) When do you expect that 50.1% will be achieved (due to small share-holders stupidly continuing to sell NEU) - i.e. which month in 2024 ?
and
b) What (approx.) minimum take-over pricing will be acceptable for the group of major shareholders (i.e. the grouping you are in) ?
Many thanks in advance.
wasa
- Forums
- ASX - By Stock
- NEU
- Ann: 2023 Annual Report to shareholders
NEU
neuren pharmaceuticals limited
Add to My Watchlist
2.96%
!
$13.23

Ann: 2023 Annual Report to shareholders, page-35
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.23 |
Change
0.380(2.96%) |
Mkt cap ! $1.652B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $4.258M | 324.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 83 | $13.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.24 | 120 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 313 | 13.230 |
6 | 550 | 13.220 |
16 | 3126 | 13.210 |
8 | 1680 | 13.200 |
4 | 1270 | 13.190 |
Price($) | Vol. | No. |
---|---|---|
13.250 | 115 | 5 |
13.260 | 867 | 11 |
13.270 | 1648 | 10 |
13.280 | 1495 | 8 |
13.290 | 2261 | 6 |
Last trade - 12.17pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online